110 related articles for article (PubMed ID: 1422609)
1. Life events and schizophrenic relapse after withdrawal of medication.
Ventura J; Nuechterlein KH; Hardesty JP; Gitlin M
Br J Psychiatry; 1992 Nov; 161():615-20. PubMed ID: 1422609
[TBL] [Abstract][Full Text] [Related]
2. Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication.
Ravaris CL; Weaver LA; Brooks GW
Am J Psychiatry; 1967 Aug; 124(2):248-9. PubMed ID: 4952779
[No Abstract] [Full Text] [Related]
3. Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Nuechterlein KH; Dawson ME; Gitlin M; Ventura J; Goldstein MJ; Snyder KS; Yee CM; Mintz J
Schizophr Bull; 1992; 18(3):387-425. PubMed ID: 1411329
[TBL] [Abstract][Full Text] [Related]
4. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
[TBL] [Abstract][Full Text] [Related]
5. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.
Wistedt B; Jørgensen A; Wiles D
Psychopharmacology (Berl); 1982; 78(4):301-4. PubMed ID: 6818587
[TBL] [Abstract][Full Text] [Related]
6. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
7. [Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
Steiner S
Psychiatr Clin (Basel); 1980; 13(3-4):165-78. PubMed ID: 7244281
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
[TBL] [Abstract][Full Text] [Related]
9. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
[TBL] [Abstract][Full Text] [Related]
10. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
11. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
12. Long-term fluphenazine decanoate maintenance dosage requirements of chronic schizophrenic patients.
Capstick N
Acta Psychiatr Scand; 1980 Mar; 61(3):256-62. PubMed ID: 7376929
[TBL] [Abstract][Full Text] [Related]
13. The vulnerability/stress model of schizophrenic relapse: a longitudinal study.
Nuechterlein KH; Dawson ME; Ventura J; Gitlin M; Subotnik KL; Snyder KS; Mintz J; Bartzokis G
Acta Psychiatr Scand Suppl; 1994; 382():58-64. PubMed ID: 8091999
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
17. Depot fluphenazine: risk/benefit ratio.
Glazer WM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
[TBL] [Abstract][Full Text] [Related]
18. Fluphenazine decanoate: a clinical problem?
Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
[TBL] [Abstract][Full Text] [Related]
19. Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.
Nuechterlein KH; Snyder KS; Dawson ME; Rappe S; Gitlin M; Fogelson D
Psychopharmacol Bull; 1986; 22(3):633-9. PubMed ID: 3797570
[No Abstract] [Full Text] [Related]
20. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome.
Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC
Br J Psychiatry; 1985 May; 146():474-80. PubMed ID: 3893600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
